71 related articles for article (PubMed ID: 15775444)
1. [Therapeutic agents for hyperphosphatemia].
Kurihara S
Clin Calcium; 2002 Oct; 12(10):1435-41. PubMed ID: 15775444
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
4. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride.
Sonikian MA; Pani IT; Iliopoulos AN; Koutala KG; Marioli SI; Vlassopoulos DA
Ren Fail; 2005; 27(2):143-7. PubMed ID: 15807177
[TBL] [Abstract][Full Text] [Related]
5. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
Nolan CR
Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients.
Block GA
Clin Nephrol; 2000 Oct; 54(4):318-24. PubMed ID: 11076108
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
Yokoyama T; Onodera Y; Mano T
Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
[TBL] [Abstract][Full Text] [Related]
9. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
[TBL] [Abstract][Full Text] [Related]
10. Control of hyperphosphatemia among patients with ESRD.
Coladonato JA
J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
[TBL] [Abstract][Full Text] [Related]
11. Introduction to sevelamer hydrochloride and its clinical effects.
Tahara H; Tsujimoto Y; Shoji T; Inaba M; Tabata T; Nishizawa Y
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S2-6. PubMed ID: 16109137
[TBL] [Abstract][Full Text] [Related]
12. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
13. [Management of hyperphosphatemia ; phosphate-binder].
Yokoyama K
Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
[TBL] [Abstract][Full Text] [Related]
14. Oral phosphate binders: history and prospects.
Kazama JJ
Bone; 2009 Jul; 45 Suppl 1():S8-12. PubMed ID: 19442621
[TBL] [Abstract][Full Text] [Related]
15. Management of secondary hyperparathyroidism.
Cunningham J
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S35-40. PubMed ID: 16109140
[TBL] [Abstract][Full Text] [Related]
16. Calcium-based phosphate binders are appropriate in chronic renal failure.
Friedman EA
Clin J Am Soc Nephrol; 2006 Jul; 1(4):704-9. PubMed ID: 17699276
[TBL] [Abstract][Full Text] [Related]
17. Review of dialysate calcium concentration in hemodialysis.
Toussaint N; Cooney P; Kerr PG
Hemodial Int; 2006 Oct; 10(4):326-37. PubMed ID: 17014507
[TBL] [Abstract][Full Text] [Related]
18. [Control of calcium and phosphate metabolism and prevention of vascular calcifications in uremic patients].
Malberti F; Ravani P
G Ital Nefrol; 2005; 22 Suppl 31():S47-52. PubMed ID: 15786402
[TBL] [Abstract][Full Text] [Related]
19. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management.
Spasovski G; Massy Z; Vanholder R
Semin Dial; 2009; 22(4):357-62. PubMed ID: 19708981
[TBL] [Abstract][Full Text] [Related]
20. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M
Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
